AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration ...

The FDA approved Mavyret for the treatment of patients 3 years and older with acute or chronic HCV infection without cirrhosis or with compensated cirrhosis.

AbbVie has received approval from the U.S. Food and Drug Administration (FDA) for a label expansion for MAVYRET ...

AbbVie’s Mavyret receives US FDA label expansion approval for treatment of chronic hepatitis C virus: North Chicago Saturday, June 14, 2025, 11:00 Hrs [IST] AbbVie announced tha ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

This strategy aligns with the company’s historical approach, as seen with its successful collaboration with AbbVie (NYSE:ABBV) on Mavyret for hepatitis C. The potential for partnerships extends ...

This strategy aligns with the company’s historical approach, as seen with its successful collaboration with AbbVie (NYSE:ABBV) on Mavyret for hepatitis C. The potential for partnerships extends beyond ...

US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.